May 28, 2026
TOBY Received FDA Breakthrough Device Designation for Its Urine-Based Alzheimer's Disease Diagnostic Test On 26 May 2026, TOBY, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Device Designation to the TOBY Test for Alzheimer’s Disease. The designation recognized th...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper